You are here


CASUS, a urine-based solution to screen for cervical cancer

Novosanis (Belgium) has been co-awarded a CASUS grant by Eurostars, a European Union (EU) program dedicated to supporting R&D-performing Small and Medium Sized Enterprises (SMEs). The project will be done in collaboration with Self-Screen (The Netherlands) and two academic partners - the University of Antwerp and Amsterdam UMC (Vrije Universiteit Amsterdam).

CASUS allows Novosanis to build a next-generation of its urine capturing device, Colli-Pee®, to offer a molecular screening solution for cervical cancer screening based on first-void urine self-sampling. Several studies have demonstrated the possibility of first-void urine for detecting high-risk types of Human Papillomavirus (HPV), the primary cause of cervical cancer. The device will be used alongside Self-screens’ HPV and cervical cancer biomarker detection assays.  

CASUS will be the first fully integrated and molecular, non-invasive cervical cancer screening kit on the market, which offers a solution to improve participation in cervical cancer screening programs across the EU.